Option Care Health (NASDAQ:OPCH) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Option Care Health (NASDAQ:OPCH) announced its quarterly earnings results on Wednesday. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02, FiscalAI reports. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.The business had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the previous year, the firm earned $0.41 EPS. Option Care Health’s quarterly revenue was up 1.9% on a year-over-year basis. Option Care Health updated its FY 2026 guidance to 1.850-1.920 EPS.

Here are the key takeaways from Option Care Health’s conference call:

• Second-quarter results exceeded expectations: Revenue rose 2% year over year to $1.4 billion, adjusted EBITDA increased 3% to $117.5 million, adjusted EPS grew to $0.45, and operating cash flow reached $184 million.
• The acute therapy portfolio delivered another quarter of high-single-digit organic growth, while IG Neuro and rare-and-orphan therapies also posted sequential and year-over-year growth. The company added five ambulatory infusion facilities, with clinic visits up more than 20% year over year.
• Management reported stabilization and sequential patient-census growth in its chronic inflammatory disease portfolio after the first-quarter reset, and expects further improvement through the remainder of 2026. Commercial-team realignment, technology deployment, and AI-enabled workflow improvements are intended to support additional revenue and productivity gains into 2027.
• Option Care repurchased $150 million of stock during the quarter—nearly 5% of shares outstanding—while ending the period with a 2.1x net debt-to-leverage ratio and $525 million remaining under its authorization.
• Full-year revenue guidance was maintained at $5.675 billion–$5.775 billion, while adjusted EBITDA guidance narrowed to $480 million–$495 million and adjusted EPS to $1.85–$1.92. Management continues to expect approximately 600 basis points of revenue pressure and a $55 million gross-profit headwind from the chronic inflammatory disease portfolio in 2026.

Option Care Health Trading Down 3.8%

OPCH stock traded down $0.92 during midday trading on Thursday, reaching $23.01. The stock had a trading volume of 2,365,326 shares, compared to its average volume of 2,542,231. The company has a quick ratio of 1.07, a current ratio of 1.64 and a debt-to-equity ratio of 0.85. Option Care Health has a twelve month low of $18.01 and a twelve month high of $36.80. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of 17.83, a PEG ratio of 1.25 and a beta of 0.65. The business has a fifty day simple moving average of $21.43 and a two-hundred day simple moving average of $26.89.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on OPCH shares. UBS Group reiterated a “buy” rating on shares of Option Care Health in a research report on Tuesday, June 16th. Zacks Research upgraded Option Care Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. JPMorgan Chase & Co. cut their price target on Option Care Health from $40.00 to $33.00 and set an “overweight” rating for the company in a report on Monday, May 4th. TD Cowen reduced their price target on shares of Option Care Health from $37.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Finally, Stephens reissued an “equal weight” rating and set a $24.00 price objective (down from $30.00) on shares of Option Care Health in a report on Friday, July 17th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Option Care Health has an average rating of “Hold” and an average price target of $29.92.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Timothy P. Sullivan purchased 24,154 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average cost of $20.69 per share, with a total value of $499,746.26. Following the completion of the purchase, the director directly owned 73,383 shares in the company, valued at approximately $1,518,294.27. This represents a 49.06% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Charles Rademacher bought 12,500 shares of the stock in a transaction on Monday, May 4th. The shares were acquired at an average cost of $21.18 per share, with a total value of $264,750.00. Following the acquisition, the chief executive officer directly owned 695,152 shares in the company, valued at approximately $14,723,319.36. This trade represents a 1.83% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 73,264 shares of company stock worth $1,548,316 in the last quarter. 1.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Option Care Health

Institutional investors have recently modified their holdings of the stock. Duquesne Family Office LLC grew its holdings in Option Care Health by 53.5% during the third quarter. Duquesne Family Office LLC now owns 977,685 shares of the company’s stock valued at $27,141,000 after purchasing an additional 340,835 shares during the period. Goldman Sachs Group Inc. raised its holdings in Option Care Health by 21.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 912,842 shares of the company’s stock worth $29,083,000 after purchasing an additional 163,835 shares during the period. Freestone Grove Partners LP bought a new position in shares of Option Care Health during the fourth quarter worth $29,181,000. Two Sigma Investments LP boosted its position in shares of Option Care Health by 26.8% during the third quarter. Two Sigma Investments LP now owns 1,129,217 shares of the company’s stock worth $31,347,000 after purchasing an additional 238,669 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Option Care Health by 250.2% in the 3rd quarter. UBS Group AG now owns 1,165,525 shares of the company’s stock valued at $32,355,000 after buying an additional 832,720 shares during the period. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Option Care Health

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. Option Care reported adjusted earnings of $0.45 per share, above estimates ranging from $0.42 to $0.43 and up from $0.41 a year earlier. Revenue reached $1.44 billion, exceeding the $1.42 billion consensus and increasing 1.9% year over year. Option Care Health Announces Financial Results for the Second Quarter
• Positive Sentiment: Full-year EPS guidance was raised above analyst expectations. Management guided to fiscal 2026 earnings of $1.85-$1.92 per share, compared with the $1.80 consensus estimate. Revenue guidance of $5.7-$5.8 billion was broadly in line with expectations, supporting the earnings outlook. Option Care Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The earnings call reinforced the favorable results. Coverage highlighted stronger-than-expected sales and earnings, which helped drive the stock’s initial positive reaction. Option Care Health Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Despite the earnings beat, quarterly revenue growth was relatively modest at 1.9%, and management’s revenue outlook was only consistent with the existing consensus. That may limit upside for investors focused on accelerating growth. Option Care Q2 Earnings Snapshot

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.